Absci Corp
ABSI3.570USD
+0.010+0.28%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
534.59MMarket Cap
LossP/E TTM
More Details of Absci Corp Company
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Absci Corp Info
Ticker SymbolABSI
Company nameAbsci Corp
IPO dateJul 22, 2021
CEOMcclain (Sean)
Number of employees156
Security typeOrdinary Share
Fiscal year-endJul 22
Address18105 Se Mill Plain Blvd
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98683
Phone13609491041
Websitehttps://www.absci.com/
Ticker SymbolABSI
IPO dateJul 22, 2021
CEOMcclain (Sean)
Company Executives of Absci Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.70M
-0.27%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
128.39K
-2.35%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
116.59K
-6.66%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Director
Director
--
--
Mr. Frans Van Houten
Mr. Frans Van Houten
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Joseph Sirosh, Ph.D.
Dr. Joseph Sirosh, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.70M
-0.27%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
128.39K
-2.35%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
116.59K
-6.66%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.69%
ARK Investment Management LLC
8.09%
BlackRock Institutional Trust Company, N.A.
6.40%
McClain (Sean)
5.79%
Redmile Group, LLC
5.49%
Other
59.55%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.69%
ARK Investment Management LLC
8.09%
BlackRock Institutional Trust Company, N.A.
6.40%
McClain (Sean)
5.79%
Redmile Group, LLC
5.49%
Other
59.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.23%
Investment Advisor/Hedge Fund
19.17%
Individual Investor
6.25%
Corporation
3.16%
Hedge Fund
3.02%
Research Firm
1.03%
Bank and Trust
0.35%
Venture Capital
0.18%
Insurance Company
0.03%
Other
24.58%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
313
99.31M
64.99%
+25.27K
2025Q3
316
99.28M
65.44%
+9.55M
2025Q2
301
89.71M
72.80%
+4.31M
2025Q1
303
85.95M
63.97%
+4.37M
2024Q4
288
73.69M
67.42%
+1.90M
2024Q3
268
71.79M
66.45%
+2.35M
2024Q2
244
67.35M
55.07%
+7.11M
2024Q1
228
60.23M
39.87%
+15.27M
2023Q4
193
33.79M
43.60%
+144.66K
2023Q3
186
33.65M
44.79%
-664.77K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
19.13M
12.8%
+747.00K
+4.06%
Jun 30, 2025
ARK Investment Management LLC
10.05M
6.72%
-909.16K
-8.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.45M
4.98%
+1.20M
+19.14%
Jun 30, 2025
McClain (Sean)
8.73M
5.84%
+119.00K
+1.38%
Mar 31, 2025
Redmile Group, LLC
8.25M
5.52%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
6.45M
4.31%
+1.76M
+37.63%
Jun 30, 2025
Phoenix Ventures Partners II LP.
4.75M
3.17%
-4.61M
-49.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.45M
1.64%
+448.98K
+22.49%
Jun 30, 2025
Columbia Wanger Asset Management, LLC
2.40M
1.61%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
4.49%
WisdomTree BioRevolution Fund
1.34%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
View more
ARK Genomic Revolution ETF
Proportion4.49%
WisdomTree BioRevolution Fund
Proportion1.34%
iShares Micro-Cap ETF
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
iShares Russell 2000 Growth ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Absci Corp?
The top five shareholders of Absci Corp are:
Fidelity Management & Research Company LLC holds 19.13M shares, accounting for 12.80% of the total shares.
ARK Investment Management LLC holds 10.05M shares, accounting for 6.72% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.45M shares, accounting for 4.98% of the total shares.
McClain (Sean) holds 8.73M shares, accounting for 5.84% of the total shares.
Redmile Group, LLC holds 8.25M shares, accounting for 5.52% of the total shares.
Fidelity Management & Research Company LLC holds 19.13M shares, accounting for 12.80% of the total shares.
ARK Investment Management LLC holds 10.05M shares, accounting for 6.72% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.45M shares, accounting for 4.98% of the total shares.
McClain (Sean) holds 8.73M shares, accounting for 5.84% of the total shares.
Redmile Group, LLC holds 8.25M shares, accounting for 5.52% of the total shares.
What are the top three shareholder types of Absci Corp?
The top three shareholder types of Absci Corp are:
Fidelity Management & Research Company LLC
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Absci Corp (ABSI)?
As of 2025Q4, 313 institutions hold shares of Absci Corp, with a combined market value of approximately 99.31M, accounting for 64.99% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.45%.
What is the biggest source of revenue for Absci Corp?
In --, the -- business generated the highest revenue for Absci Corp, amounting to -- and accounting for --% of total revenue.
